文献速递临床试验与 GCP

成人流感住院患者抗病毒治疗:评估玛巴洛沙韦缩短临床改善时间及降低重症并发症风险的多中心随机安慰剂对照试验(INFLUENT试验)研究方案

Antiviral treatment in adult patients hospitalized for influenza: study protocol for a multi-center, randomized, placebo-controlled trial on the efficacy of baloxavir marboxil to reduce time to clinical improvement and the risk for severe complications (the INFLUENT trial).
PubMed 文献 · Trials · 2025-11-24

本研究为研究者发起的多中心、随机、三盲、安慰剂对照优效性试验,计划在四个瑞士大型医院连续三个流感季招募484例确诊流感且NEWS2评分≥4的成人免疫正常住院患者,评估单剂玛巴洛沙韦缩短临床改善时间的疗效。主要结局为从给药至NEWS2评分≤2维持24小时或出院(以先发生者为准)的时间(小时),并在症状出现后72小时内早期治疗者中另行计算。

要点

  • 针对成人流感住院患者缺乏安慰剂对照试验的空白,评估单剂玛巴洛沙韦的临床获益。
  • 主要结局为从给药至NEWS2评分≤2维持24小时或出院的时间(小时)。
  • 试验结果无论阳性或阴性均将影响临床指导。

核心结论

  • 该试验结果无论阳性或阴性均将影响临床指导。
  • 若证实玛巴洛沙韦临床获益,单剂口服药将是季节性大流行或新流感大流行时最易实施的治疗选择。
  • 若未显示明确治疗获益,住院患者抗病毒治疗的实施可被重新考虑,以避免不必要的用药、降低治疗过度使用相关的耐药风险并最终节省不必要的治疗相关费用。

研究设计与样本

  • 研究者发起的多中心、随机、三盲、安慰剂对照优效性试验。
  • 计划招募484例确诊流感且NEWS2评分≥4的成人免疫正常住院患者。
  • 在四个瑞士大型医院连续三个流感季招募。

主要发现

  • 主要结局为从给药至NEWS2评分≤2维持24小时或出院(以先发生者为准)的时间(小时)。
  • 主要结局在所有患者中计算,不考虑给药时症状持续时间,并在症状出现后72小时内早期治疗的参与者中另行计算。
  • 主要次要结局包括严重流感并发症风险、住院时长及给药后第3天病毒载量差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Seasonal influenza virus leads to more than half a million deaths each year worldwide. Due to its capacity to evolve, it is considered the most likely pathogen to cause a future pandemic. Antiviral treatment options are currently limited, with the most widely used drugs being neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir marboxil. In adult hospitalized patients, due to the lack of placebo-controlled trials, current available evidence on antiviral treatment benefits is essentially based on observational studies. A placebo-controlled clinical trial is needed to fill this knowledge gap. METHODS: This is an investigator-initiated, randomized, triple-blind, placebo-controlled, superiority, multi-center trial to assess the clinical efficacy of single-dose baloxavir in decreasing time to clinical improvement in adult immunocompetent patients hospitalized with influenza. Patients (n = 484) with confirmed, severe infection (NEWS2 score ≥ 4) will be recruited over three influenza seasons in four large Swiss hospitals. PRIMARY OUTCOME: time to clinical improvement (in hours), calculated from treatment administration until NEWS2 score ≤ 2 maintained for 24 h or until hospital discharge, whichever comes first. The primary outcome is calculated in all patients independently of the duration of symptoms at treatment administration, as well as in participants treated early (<72 h) post onset of symptoms. The main secondary outcomes are the risk of serious influenza complications, length of hospitalization, and difference in viral load at D3 post-treatment administration. DISCUSSION: This trial's results, whether positive or negative, will impact clinical guidance. If baloxavir's clinical benefit is demonstrated, a single-dose pill would be the easiest implementable treatment option in case of large seasonal outbreaks or a new influenza pandemic. If a clear treatment benefit is not shown, antiviral treatment administration in the hospitalized patient population could be reconsidered to prevent unnecessary medication, lower the risk of resistance development linked to treatment overuse, and ultimately save unnecessary treatment-related expenses. TRIAL REGISTRATION: ClinicalTrials.gov NCT06653569. Registered on October 22, 2024, https://clinicaltrials.gov/study/NCT06653569?term=NCT06653569&rank=1 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hosszu-Fellous K, Poncet A, Cabecinhas ARG, et al. Antiviral treatment in adult patients hospitalized for influenza: study protocol for a multi-center, randomized, placebo-controlled trial on the efficacy of baloxavir marboxil to reduce time to clinical improvement and the risk for severe complications (the INFLUENT trial). Trials. 2025. PMID: 41286959. doi:10.1186/s13063-025-09248-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。